Non Incretin Effects of DPP-4 Inhibitors: Comparative Study

A Shabbir Ali Bhatti; Aliya Shabbir; Abdul  Waheed Shehzad; M. A.Bhatti

doi:10.53685/jshmdc.v1i1.34

Authors

A Shabbir Ali Bhatti Department of Pharmacology, Shalamar Medical & Dental College, Lahore, Pakistan
Aliya Shabbir Department of Pharmacology, Shalamar Medical & Dental College, Lahore, Pakistan
Abdul Waheed Shehzad The Children Hospital and Institute of Child Health, Lahore, Pakistan
M. A.Bhatti Department of Pharmacology, Avicenna Medical College, Lahore, Pakistan

DOI:

https://doi.org/10.53685/jshmdc.v1i1.34

Keywords:

T2DM, IHD, DPP-4 Inhibitors, Apical force, dP/dt(max)

Abstract

Background: Diabetes mellitus is a metabolic syndrome that adversely affects all parts of the body especially the cardiovascular system. Dipeptidyl peptidase-4 (DPP-4) is a multifunctional protein and its inhibition has diverse effects. DPP-4 inhibition was shown to improve the survival rate after myocardial infarction in mice. Beneficial myocardial metabolic effects of DPP-4 inhibitors have been observed in experimental models. Cardiovascular outcome trials of DPP-4 inhibitors show variable adverse cardiovascular events.

Objective: This experimental study was aimed to study the direct cardiovascular effects of DPP-4 Inhibitors on chronotropicity (Heart Rate, HR), inotropicity (Apical Force and; dP/dt(max), ECG and Coronary Flow(C.F) and detect its potential useful and harmful effects on cardiovascular parameters.

Methods: The effects of graded doses (10-9 - 10-6M) of Sitagliptin (S) and Vildagliptin(V) were observed on retrograde perfused isolated rabbit hearts with warm Krebs-Henseliet solution on Radnoti working heart system. Fifty four(54) rabbits were grouped into nine groups i.e ; I(S1), II(S2), III(S3), IV(S4), V(S5), VI(S6), VII(V1), and VIII(V2) and IX(V3) each comprising of six animals(n=6).Effects of experimental drugs were observed on chronotropicity(HR), inotropicity (Apical Force and Peak rate of rise of LVP i.e; dP/dt(max) and Coronary flow(CF). The results were statistically analyzed with Graph Pad Grism and wherever necessary paired or unpaired “t” test was applied.

Conclusion: Sitagliptin and Vildagliptin both have suppressant effects on HR. Sitagliptin has positive and Vildagliptin had negative inotropic effects. Both drugs (10-8 - 10-6M); decrease coronary flow but have no significant effect on ECG.

References

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of medicine. 1998; 339(4): 229-234. DOI: https://doi.org/10.1056/NEJM199807233390404

Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non–Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000; 102(9):1014-1019. DOI: https://doi.org/10.1161/01.CIR.102.9.1014

McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. European Heart Journal. 2000; 21(21): 1750-1758. DOI: https://doi.org/10.1053/euhj.2000.2317

Lim S, Choi SH, Shin H, Cho BJ, Park HS, Ahn BY, Kang SM, Yoon JW, Jang HC, Kim YB, Park KS. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PloS one. 2012; 7(4): e35007. DOI: https://doi.org/10.1371/journal.pone.0035007

Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovascular research. 2002; 55(3): 534-543. DOI: https://doi.org/10.1016/S0008-6363(02)00455-8

Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin YU, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. American Journal of Physiology-Heart and Circulatory Physiology. 2010; 298(5): H1454-65. DOI: https://doi.org/10.1152/ajpheart.00867.2009

Xiao YF, Nikolskaya A, Jaye DA, Sigg DC. Glucagon-like peptide-1 enhances cardiac L-type Ca 2+ currents via activation of the cAMPdependent protein kinase A pathway. Cardiovascular diabetology. 2011; 10(1): 6. DOI: https://doi.org/10.1186/1475-2840-10-6

Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS mediated signaling. Diabetes. 2007. 57: 696–705. DOI: https://doi.org/10.2337/db07-1098

Huisamen B, Genis A, Marais E, Lochner A. Pretreatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovascular drugs and therapy. 2011; 25(1): 13-20.

Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970; 19: Suppl-789.

Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003 Dec 1; 144(12): 5179- 5183. DOI: https://doi.org/10.1210/en.2003-0982

Hardie DG. The AMP-activated protein kinase pathway–new players upstream and downstream. Journal of cell science. 2004; 117(23): 5479- 5487. DOI: https://doi.org/10.1242/jcs.01540

Huisamen B, Genis A, Marais E, Lochner A. Pretreatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovascular drugs and therapy. 2011; 25(1):13-20. DOI: https://doi.org/10.1007/s10557-010-6271-7

Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010 Oct 1; 56(4): 728-733. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.110.156554

Deacon CF. A review of dipeptidyl peptidase-¬‐ 4 inhibitors. Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism. 2018; 20: 34-46.

Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. The Tohoku journal of experimental medicine. 2011; 223(2): 133-135.

Lamanna C, Monami M, Bartoli N, Zannoni S, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular events: a protective effect?. In Diabetologia 2011 Sep 1 (Vol. 54, pp. S109-S109). 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER.

Deacon CF. A review of dipeptidyl peptidase- 4 inhibitors. Hot topics from randomized controlled trials. Diabetes, Obesity and Metabolism. 2018; 20: 34-46. DOI: https://doi.org/10.1111/dom.13135

Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. The Tohoku journal of experimental medicine. 2011; 223(2):133-135. DOI: https://doi.org/10.1620/tjem.223.133

Lamanna C, Monami M, Bartoli N, Zannoni S, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular events: a protective effect? In Diabetologia 2011. (Vol. 54, pp. S109-S109). 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER